Identification

Name
Moxifloxacin
Accession Number
DB00218  (APRD00281)
Type
Small Molecule
Groups
Approved, Investigational
Description

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Structure
Thumb
Synonyms
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
External IDs
BAY 12-8039
Product Ingredients
IngredientUNIICASInChI Key
Moxifloxacin hydrochlorideC53598599T186826-86-8IDIIJJHBXUESQI-DFIJPDEKSA-N
Moxifloxacin hydrochloride monohydrateB8956S8609192927-63-2SKZIMSDWAIZNDD-WJMOHVQJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MoxifloxacinSolution0.5 %OphthalmicActavis Pharma Company2015-11-04Not applicableCanada
AveloxInjection, solution400 mg/250mLIntravenousBayer2001-11-30Not applicableUs
AveloxTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2011-02-25Not applicableUs
AveloxTablet, film coated400 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-12-07Not applicableUs
AveloxTablet, film coated400 mg/1OralSchering Plough1999-12-10Not applicableUs0085 173320180814 13942 52ev3k
AveloxTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2009-07-16Not applicableUs
AveloxTablet400 mgOralBayer2000-10-20Not applicableCanada
AveloxTablet, film coated400 mg/1OralBayer1999-12-10Not applicableUs
AveloxTablet, film coated400 mg/1OralCardinal Health2010-03-022018-02-03Us
AveloxTablet, film coated400 mg/1OralRemedy Repack2013-05-242017-03-03Us00085 1733 03 nlmimage10 2619935c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moxifloxacinTablet400 mgOralApotex Corporation2016-01-11Not applicableCanada
Apo-moxifloxacinSolution0.5 %OphthalmicApotex Corporation2015-11-19Not applicableCanada
Auro-moxifloxacinTablet400 mgOralAuro Pharma Inc2015-11-04Not applicableCanada
Bio-moxifloxacinTablet400 mgOralBiomed Pharma2016-01-15Not applicableCanada
Dom-moxifloxacinTablet400 mgOralDominion PharmacalNot applicableNot applicableCanada
Ipg-moxifloxacinTablet400 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-moxifloxacinSolution0.5 %OphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-moxifloxacinTablet400 mgOralJamp Pharma Corporation2015-11-04Not applicableCanada
Jamp-moxifloxacin TabletsTablet400 mgOralJamp Pharma Corporation2016-01-11Not applicableCanada
Mar-moxifloxacinTablet400 mgOralMarcan Pharmaceuticals Inc2015-12-21Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dex-MoxiMoxifloxacin hydrochloride monohydrate (5 mg/mL) + Dexamethasone sodium phosphate (1 mg/mL)Injection, solutionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Dex-Moxi PFMoxifloxacin hydrochloride monohydrate (5 mg/mL) + Dexamethasone sodium phosphate (1 mg/mL)Injection, solutionIntraocularImprimis Rx Nj2018-01-01Not applicableUs
Dex-Moxi-KetorMoxifloxacin hydrochloride monohydrate (.5 mg/mL) + Dexamethasone sodium phosphate (1 mg/mL) + Ketorolac tromethamine (.4 mg/mL)Injection, solutionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
DexMoxiKetor PFMoxifloxacin hydrochloride monohydrate (.5 mg/mL) + Dexamethasone sodium phosphate (1 mg/mL) + Ketorolac tromethamine (.4 mg/mL)Injection, solutionIntraocularImprimis Rx Nj2018-01-01Not applicableUs
Moxifloxacin PFMoxifloxacin hydrochloride monohydrate (5 mg/mL)Injection, solutionIntraocularImprimis Rx Nj2018-01-01Not applicableUs
Moxifloxacin PFMoxifloxacin hydrochloride monohydrate (5 mg/mL)Injection, solutionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Triamcinolone-Moxifloxacin PFMoxifloxacin hydrochloride monohydrate (1 mg/mL) + Triamcinolone acetonide (15 mg/mL)Injection, suspensionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Triamcinolone-Moxifloxacin PFMoxifloxacin hydrochloride (1 mg/mL) + Triamcinolone acetonide (15 mg/mL)SuspensionOphthalmicImprimis Rx Nj2018-01-01Not applicableUs
Categories
UNII
U188XYD42P
CAS number
151096-09-2
Weight
Average: 401.4314
Monoisotopic: 401.175084476
Chemical Formula
C21H24FN3O4
InChI Key
FABPRXSRWADJSP-MEDUHNTESA-N
InChI
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
IUPAC Name
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O

Pharmacology

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions
Pharmacodynamics

Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, and Streptococcus viridans group. Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, and Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.
Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Mechanism of action

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

TargetActionsOrganism
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UDNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

Volume of distribution
  • 1.7 to 2.7 L/kg
Protein binding

50% bound to serum proteins, independent of drug concentration.

Metabolism

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose.

Route of elimination

Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).

Half life

11.5-15.6 hours (single dose, oral)

Clearance
  • 12 +/- 2 L/hr
Toxicity

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Moxifloxacin.Experimental
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Moxifloxacin.Experimental, Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Moxifloxacin.Investigational
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Moxifloxacin.Experimental
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Moxifloxacin.Experimental
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Moxifloxacin.Investigational
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Moxifloxacin.Experimental
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Moxifloxacin.Experimental
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Moxifloxacin.Experimental
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Moxifloxacin.Approved
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Moxifloxacin.Experimental
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Moxifloxacin.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Abexinostat.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
AcefyllineThe metabolism of Acefylline can be decreased when combined with Moxifloxacin.Experimental
AcemetacinAcemetacin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Experimental, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Moxifloxacin.Approved, Investigational
AceprometazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Moxifloxacin.Approved, Investigational, Withdrawn
Acetylcysteine zincAcetylcysteine zinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Moxifloxacin.Approved
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Moxifloxacin.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Moxifloxacin.Experimental, Investigational
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Moxifloxacin.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Moxifloxacin.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of tendinopathy can be increased when Alclometasone is combined with Moxifloxacin.Approved
AldosteroneThe risk or severity of tendinopathy can be increased when Aldosterone is combined with Moxifloxacin.Experimental, Investigational
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Moxifloxacin.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Moxifloxacin.Approved, Vet Approved
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Moxifloxacin.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Moxifloxacin.Approved
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Moxifloxacin.Approved
AmcinonideThe risk or severity of tendinopathy can be increased when Amcinonide is combined with Moxifloxacin.Approved
AMG-222The therapeutic efficacy of AMG-222 can be increased when used in combination with Moxifloxacin.Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amifampridine.Approved
AminophenazoneAminophenazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amitriptyline.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Moxifloxacin.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Moxifloxacin.Approved
AnagliptinThe therapeutic efficacy of Anagliptin can be increased when used in combination with Moxifloxacin.Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Antazoline.Approved
AntipyrineAntipyrine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
AntrafenineAntrafenine may increase the neuroexcitatory activities of Moxifloxacin.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moxifloxacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Moxifloxacin.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Moxifloxacin.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Moxifloxacin.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moxifloxacin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Moxifloxacin.Approved
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Moxifloxacin.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Moxifloxacin.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Moxifloxacin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Moxifloxacin.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Moxifloxacin.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Moxifloxacin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be increased when used in combination with Moxifloxacin.Investigational
BalsalazideBalsalazide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
BamifyllineThe metabolism of Bamifylline can be decreased when combined with Moxifloxacin.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Moxifloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Moxifloxacin.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Moxifloxacin.Investigational
BendazacBendazac may increase the neuroexcitatory activities of Moxifloxacin.Experimental
BenfluorexThe therapeutic efficacy of Benfluorex can be increased when used in combination with Moxifloxacin.Investigational, Withdrawn
BenorilateBenorilate may increase the neuroexcitatory activities of Moxifloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Moxifloxacin.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Moxifloxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of tendinopathy can be increased when Betamethasone is combined with Moxifloxacin.Approved, Vet Approved
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Moxifloxacin.Approved, Investigational
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moxifloxacin.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Moxifloxacin.Approved
BromocriptineThe therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.Approved, Investigational
BromotheophyllineThe metabolism of Bromotheophylline can be decreased when combined with Moxifloxacin.Approved
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Moxifloxacin.Approved
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Moxifloxacin.Approved
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Moxifloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be increased when used in combination with Moxifloxacin.Investigational, Withdrawn
BufyllineThe metabolism of Bufylline can be decreased when combined with Moxifloxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Moxifloxacin.Approved, Investigational
ButriptylineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Butriptyline.Approved
CafedrineThe metabolism of Cafedrine can be decreased when combined with Moxifloxacin.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Moxifloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be increased when used in combination with Moxifloxacin.Experimental
CarmegliptinThe therapeutic efficacy of Carmegliptin can be increased when used in combination with Moxifloxacin.Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved, Withdrawn
CelecoxibCelecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
CeritinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Moxifloxacin.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Moxifloxacin.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.Approved, Investigational
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Moxifloxacin.Approved, Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Moxifloxacin.Approved
CiclesonideThe risk or severity of tendinopathy can be increased when Ciclesonide is combined with Moxifloxacin.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Moxifloxacin.Experimental
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Moxifloxacin.Approved, Investigational
CimicoxibCimicoxib may increase the neuroexcitatory activities of Moxifloxacin.Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of tendinopathy can be increased when Clobetasol is combined with Moxifloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of tendinopathy can be increased when Clobetasol propionate is combined with Moxifloxacin.Approved
ClobetasoneThe risk or severity of tendinopathy can be increased when Clobetasone is combined with Moxifloxacin.Approved
ClocortoloneThe risk or severity of tendinopathy can be increased when Clocortolone is combined with Moxifloxacin.Approved
ClomipramineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Moxifloxacin.Approved
CloprednolThe risk or severity of tendinopathy can be increased when Cloprednol is combined with Moxifloxacin.Experimental
ClorindioneThe therapeutic efficacy of Clorindione can be increased when used in combination with Moxifloxacin.Experimental
ClozapineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cocaine.Approved, Illicit
CorticotropinThe risk or severity of tendinopathy can be increased when Corticotropin is combined with Moxifloxacin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of tendinopathy can be increased when Cortisone acetate is combined with Moxifloxacin.Approved, Investigational
CortivazolThe risk or severity of tendinopathy can be increased when Cortivazol is combined with Moxifloxacin.Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Moxifloxacin.Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Moxifloxacin.Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Moxifloxacin.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.Approved
DasatinibThe risk or severity of QTc prolongation can be increased when Dasatinib is combined with Moxifloxacin.Approved, Investigational
DeflazacortThe risk or severity of tendinopathy can be increased when Deflazacort is combined with Moxifloxacin.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Moxifloxacin.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Delamanid.Approved, Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Moxifloxacin.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Moxifloxacin.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Desloratadine.Approved, Investigational
DesonideThe risk or severity of tendinopathy can be increased when Desonide is combined with Moxifloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of tendinopathy can be increased when Desoximetasone is combined with Moxifloxacin.Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Moxifloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of tendinopathy can be increased when Dexamethasone isonicotinate is combined with Moxifloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine maleate.Approved
DexibuprofenDexibuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
DexketoprofenDexketoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
DiclofenacDiclofenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Moxifloxacin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Moxifloxacin.Experimental
DiflorasoneThe risk or severity of tendinopathy can be increased when Diflorasone is combined with Moxifloxacin.Approved
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Moxifloxacin.Vet Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of tendinopathy can be increased when Difluocortolone is combined with Moxifloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of tendinopathy can be increased when Difluprednate is combined with Moxifloxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dimenhydrinate.Approved
DiphenadioneThe therapeutic efficacy of Diphenadione can be increased when used in combination with Moxifloxacin.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Moxifloxacin.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.Approved
Ditiocarb ZincDitiocarb Zinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Moxifloxacin.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Moxifloxacin.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Moxifloxacin.Approved, Investigational
DoxofyllineThe metabolism of Doxofylline can be decreased when combined with Moxifloxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Moxifloxacin.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Droperidol.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.Approved, Investigational
DutogliptinThe therapeutic efficacy of Dutogliptin can be increased when used in combination with Moxifloxacin.Investigational
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Moxifloxacin.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Emedastine.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be increased when used in combination with Moxifloxacin.Experimental
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Moxifloxacin.Approved, Investigational
EntecavirThe metabolism of Entecavir can be decreased when combined with Moxifloxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entinostat.Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Moxifloxacin.Approved, Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Moxifloxacin.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Moxifloxacin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Moxifloxacin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Escitalopram.Approved, Investigational
EtamiphyllineThe metabolism of Etamiphylline can be decreased when combined with Moxifloxacin.Experimental
EthenzamideEthenzamide may increase the neuroexcitatory activities of Moxifloxacin.Experimental
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Moxifloxacin.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
EvogliptinThe therapeutic efficacy of Evogliptin can be increased when used in combination with Moxifloxacin.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be increased when used in combination with Moxifloxacin.Approved, Investigational
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Moxifloxacin.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Moxifloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Moxifloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Moxifloxacin.Approved
FenethyllineThe metabolism of Fenethylline can be decreased when combined with Moxifloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Moxifloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
Ferric ammonium citrateFerric ammonium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseFerric Carboxymaltose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationFerric cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideFerric hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideFerric oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateFerric pyrophosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric pyrophosphate citrateFerric pyrophosphate citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric subsulfateFerric subsulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateFerric sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateFerrous bisglycinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideFerrous chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateFerrous fumarate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateFerrous gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateFerrous succinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateFerrous sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesFerumoxides can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilFerumoxsil can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolFerumoxytol can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Moxifloxacin.Approved, Investigational
FirocoxibFirocoxib may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Vet Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Moxifloxacin.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
FlucloroloneThe risk or severity of tendinopathy can be increased when Fluclorolone is combined with Moxifloxacin.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Moxifloxacin.Approved, Investigational
FludrocortisoneThe risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Moxifloxacin.Approved, Investigational
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Moxifloxacin.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Moxifloxacin.Withdrawn
FlumethasoneThe risk or severity of tendinopathy can be increased when Flumethasone is combined with Moxifloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of tendinopathy can be increased when Flunisolide is combined with Moxifloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Moxifloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Moxifloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of tendinopathy can be increased when Fluocinolone Acetonide is combined with Moxifloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of tendinopathy can be increased when Fluocinonide is combined with Moxifloxacin.Approved, Investigational
FluocortinThe risk or severity of tendinopathy can be increased when Fluocortin is combined with Moxifloxacin.Experimental
FluocortoloneThe risk or severity of tendinopathy can be increased when Fluocortolone is combined with Moxifloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of tendinopathy can be increased when Fluorometholone is combined with Moxifloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of tendinopathy can be increased when Fluperolone is combined with Moxifloxacin.Experimental
FluprednideneThe risk or severity of tendinopathy can be increased when Fluprednidene is combined with Moxifloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of tendinopathy can be increased when Fluprednisolone is combined with Moxifloxacin.Approved
FlurandrenolideThe risk or severity of tendinopathy can be increased when Flurandrenolide is combined with Moxifloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
FluticasoneThe risk or severity of tendinopathy can be increased when Fluticasone is combined with Moxifloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Moxifloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Moxifloxacin.Approved
FormocortalThe risk or severity of tendinopathy can be increased when Formocortal is combined with Moxifloxacin.Experimental
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Moxifloxacin.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Moxifloxacin.Approved
FurafyllineThe metabolism of Furafylline can be decreased when combined with Moxifloxacin.Experimental
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Moxifloxacin.Approved
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Moxifloxacin.Approved, Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Moxifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gemifloxacin.Approved, Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be increased when used in combination with Moxifloxacin.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Moxifloxacin.Investigational
GleptoferronGleptoferron can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be increased when used in combination with Moxifloxacin.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be increased when used in combination with Moxifloxacin.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Moxifloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Moxifloxacin.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be increased when used in combination with Moxifloxacin.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.Approved
GlycodiazineThe therapeutic efficacy of Glycodiazine can be increased when used in combination with Moxifloxacin.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be increased when used in combination with Moxifloxacin.Investigational
GranisetronThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the neuroexcitatory activities of Moxifloxacin.Experimental
GuanineThe metabolism of Guanine can be decreased when combined with Moxifloxacin.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be increased when used in combination with Moxifloxacin.Experimental
HalcinonideThe risk or severity of tendinopathy can be increased when Halcinonide is combined with Moxifloxacin.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Halofantrine.Approved
HalometasoneThe risk or severity of tendinopathy can be increased when Halometasone is combined with Moxifloxacin.Experimental
HaloperidolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Moxifloxacin.Approved
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Moxifloxacin.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of tendinopathy can be increased when Hydrocortisone aceponate is combined with Moxifloxacin.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Moxifloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Moxifloxacin.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of tendinopathy can be increased when Hydrocortisone probutate is combined with Moxifloxacin.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of tendinopathy can be increased when Hydrocortisone succinate is combined with Moxifloxacin.Approved
Hydrocortisone valerateThe risk or severity of tendinopathy can be increased when Hydrocortisone valerate is combined with Moxifloxacin.Approved, Vet Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Moxifloxacin.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Moxifloxacin.Approved
HypoxanthineThe metabolism of Hypoxanthine can be decreased when combined with Moxifloxacin.Experimental
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ibutilide.Approved
IcosapentIcosapent may increase the neuroexcitatory activities of Moxifloxacin.Approved, Nutraceutical
IloperidoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Moxifloxacin.Experimental
ImipramineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Imipramine.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Moxifloxacin.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Moxifloxacin.Approved
IndobufenIndobufen may increase the neuroexcitatory activities of Moxifloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be increased when used in combination with Moxifloxacin.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be increased when used in combination with Moxifloxacin.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be increased when used in combination with Moxifloxacin.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be increased when used in combination with Moxifloxacin.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Moxifloxacin.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be increased when used in combination with Moxifloxacin.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Moxifloxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Moxifloxacin.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be increased when used in combination with Moxifloxacin.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be increased when used in combination with Moxifloxacin.Approved
IronIron can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranIron Dextran can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Iron isomaltoside 1000 can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateIron saccharate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Moxifloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Moxifloxacin.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Moxifloxacin.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivosidenib.Approved, Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Moxifloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Moxifloxacin.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Moxifloxacin.Approved
KRP-104The therapeutic efficacy of KRP-104 can be increased when used in combination with Moxifloxacin.Investigational
Lanthanum carbonateLanthanum carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Moxifloxacin.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Moxifloxacin.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Moxifloxacin.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levomethadyl Acetate.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be increased when used in combination with Moxifloxacin.Approved
LisofyllineThe metabolism of Lisofylline can be decreased when combined with Moxifloxacin.Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lithium cation.Experimental
LixisenatideThe therapeutic efficacy of Lixisenatide can be increased when used in combination with Moxifloxacin.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be increased when used in combination with Moxifloxacin.Approved, Investigational
LobucavirThe metabolism of Lobucavir can be decreased when combined with Moxifloxacin.Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lomefloxacin.Approved, Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Moxifloxacin.Experimental
LopinavirThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Loratadine.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
LoteprednolThe risk or severity of tendinopathy can be increased when Loteprednol is combined with Moxifloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Macimorelin.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Moxifloxacin.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be increased when used in combination with Moxifloxacin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of tendinopathy can be increased when Medrysone is combined with Moxifloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Moxifloxacin.Approved, Investigational
MelengestrolThe risk or severity of tendinopathy can be increased when Melengestrol is combined with Moxifloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
MeprednisoneThe risk or severity of tendinopathy can be increased when Meprednisone is combined with Moxifloxacin.Approved, Investigational
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Moxifloxacin.Approved, Vet Approved
MequitazineThe risk or severity of adverse effects can be increased when Moxifloxacin is combined with Mequitazine.Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mesoridazine.Approved, Investigational
MetahexamideThe therapeutic efficacy of Metahexamide can be increased when used in combination with Moxifloxacin.Experimental
MetamizoleMetamizole may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.Approved
MethadoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Methadone.Approved
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Moxifloxacin.Approved, Investigational
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Moxifloxacin.Approved, Vet Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Moxifloxacin.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Moxifloxacin.Approved
MifepristoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be increased when used in combination with Moxifloxacin.Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Moxifloxacin.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Moxifloxacin.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be increased when used in combination with Moxifloxacin.Approved, Investigational
MocetinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mocetinostat.Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Moxifloxacin.Approved
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
MometasoneThe risk or severity of tendinopathy can be increased when Mometasone is combined with Moxifloxacin.Approved, Vet Approved
Mometasone furoateThe risk or severity of tendinopathy can be increased when Mometasone furoate is combined with Moxifloxacin.Approved, Vet Approved
MorniflumateMorniflumate may increase the neuroexcitatory activities of Moxifloxacin.Approved
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Moxifloxacin.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nalidixic Acid.Approved, Investigational
NaproxenNaproxen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be increased when used in combination with Moxifloxacin.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be increased when used in combination with Moxifloxacin.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Moxifloxacin.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nemonoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be increased when used in combination with Moxifloxacin.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Moxifloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Moxifloxacin.Investigational
NitroprussideNitroprusside can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NN344The therapeutic efficacy of NN344 can be increased when used in combination with Moxifloxacin.Investigational
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Moxifloxacin.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Moxifloxacin.Approved
NS-398NS-398 may increase the neuroexcitatory activities of Moxifloxacin.Experimental
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Moxifloxacin.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Moxifloxacin.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Moxifloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
OmarigliptinThe therapeutic efficacy of Omarigliptin can be increased when used in combination with Moxifloxacin.Investigational
OndansetronThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ondansetron.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Moxifloxacin.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Moxifloxacin.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin.Approved, Investigational
OxaprozinOxaprozin may increase the neuroexcitatory activities of Moxifloxacin.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Moxifloxacin.Experimental
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Moxifloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Papaverine.Approved, Investigational
ParamethasoneThe risk or severity of tendinopathy can be increased when Paramethasone is combined with Moxifloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Moxifloxacin.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Moxifloxacin.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Moxifloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Moxifloxacin.Approved
PeldesineThe metabolism of Peldesine can be decreased when combined with Moxifloxacin.Experimental, Investigational
PemetrexedThe metabolism of Pemetrexed can be decreased when combined with Moxifloxacin.Approved, Investigational
PenciclovirThe metabolism of Penciclovir can be decreased when combined with Moxifloxacin.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Moxifloxacin.Approved, Investigational
PentifyllineThe metabolism of Pentifylline can be decreased when combined with Moxifloxacin.Experimental
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Moxifloxacin.Approved, Investigational
PerflubutanePerflubutane can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Perflutren.Approved
PhenforminThe therapeutic efficacy of Phenformin can be increased when used in combination with Moxifloxacin.Approved, Investigational, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be increased when used in combination with Moxifloxacin.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Moxifloxacin.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Moxifloxacin.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.Approved
PimozideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Moxifloxacin.Experimental
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Moxifloxacin.Experimental
PiroxicamPiroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Moxifloxacin.Experimental
PitolisantThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pitolisant.Approved, Investigational
PolaprezincPolaprezinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Moxifloxacin.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pracinostat.Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be increased when used in combination with Moxifloxacin.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Investigational
PrednicarbateThe risk or severity of tendinopathy can be increased when Prednicarbate is combined with Moxifloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Moxifloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of tendinopathy can be increased when Prednisone is combined with Moxifloxacin.Approved, Vet Approved
PrednylideneThe risk or severity of tendinopathy can be increased when Prednylidene is combined with Moxifloxacin.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Primaquine.Approved
ProbenecidProbenecid may decrease the excretion rate of Moxifloxacin which could result in a higher serum level.Approved, Investigational
ProbucolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Procainamide.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Moxifloxacin.Experimental
PromazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Moxifloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Propafenone.Approved
PropentofyllineThe metabolism of Propentofylline can be decreased when combined with Moxifloxacin.Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Moxifloxacin.Approved, Investigational, Vet Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Moxifloxacin.Approved
ProxyphyllineThe metabolism of Proxyphylline can be decreased when combined with Moxifloxacin.Experimental
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Moxifloxacin.Investigational
Prussian bluePrussian blue can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quetiapine.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Moxifloxacin.Approved, Investigational
RepaglinideThe therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Moxifloxacin.Approved
RimexoloneThe risk or severity of tendinopathy can be increased when Rimexolone is combined with Moxifloxacin.Approved
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Moxifloxacin.Approved, Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moxifloxacin.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be increased when used in combination with Moxifloxacin.Experimental, Investigational
RobenacoxibRobenacoxib may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Vet Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Withdrawn
RomidepsinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Moxifloxacin.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Moxifloxacin.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Moxifloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Moxifloxacin.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Moxifloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Moxifloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Moxifloxacin.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Moxifloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Moxifloxacin.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Moxifloxacin.Vet Approved, Withdrawn
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Moxifloxacin.Approved
SC-236SC-236 may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Investigational
SemaglutideThe therapeutic efficacy of Semaglutide can be increased when used in combination with Moxifloxacin.Approved, Investigational
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Moxifloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Moxifloxacin.Approved, Vet Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Moxifloxacin.Approved, Investigational
Sodium feredetateSodium feredetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium ferric gluconate complexSodium ferric gluconate complex can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Moxifloxacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Moxifloxacin.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with Moxifloxacin.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sparfloxacin.Approved, Investigational
Strontium ranelateStrontium ranelate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
SucralfateSucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Moxifloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sultopride.Experimental
SunitinibThe therapeutic efficacy of Sunitinib can be increased when used in combination with Moxifloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
TalniflumateTalniflumate may increase the neuroexcitatory activities of Moxifloxacin.Approved
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Moxifloxacin.Approved
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Moxifloxacin.Investigational
TaspoglutideThe therapeutic efficacy of Taspoglutide can be increased when used in combination with Moxifloxacin.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelavancinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Temafloxacin.Withdrawn
TeneligliptinThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Moxifloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Moxifloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Moxifloxacin.Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Moxifloxacin.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tetrabenazine.Approved, Investigational
Tetraferric tricitrate decahydrateTetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TheobromineThe metabolism of Theobromine can be decreased when combined with Moxifloxacin.Approved, Investigational
TheodrenalineThe metabolism of Theodrenaline can be decreased when combined with Moxifloxacin.Investigational
ThioridazineThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Moxifloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
TioclomarolThe therapeutic efficacy of Tioclomarol can be increased when used in combination with Moxifloxacin.Experimental
TixocortolThe risk or severity of tendinopathy can be increased when Tixocortol is combined with Moxifloxacin.Approved, Withdrawn
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Moxifloxacin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be increased when used in combination with Moxifloxacin.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Moxifloxacin.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Moxifloxacin.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Toremifene.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Moxifloxacin.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Moxifloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of tendinopathy can be increased when Triamcinolone is combined with Moxifloxacin.Approved, Vet Approved
TrilostaneThe risk or severity of tendinopathy can be increased when Trilostane is combined with Moxifloxacin.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Moxifloxacin.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Moxifloxacin.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Moxifloxacin.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be increased when used in combination with Moxifloxacin.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Moxifloxacin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tucidinostat.Investigational
UlobetasolThe risk or severity of tendinopathy can be increased when Ulobetasol is combined with Moxifloxacin.Approved
Uric AcidThe metabolism of Uric Acid can be decreased when combined with Moxifloxacin.Experimental, Investigational
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Moxifloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Withdrawn
ValganciclovirThe metabolism of Valganciclovir can be decreased when combined with Moxifloxacin.Approved, Investigational
ValomaciclovirThe metabolism of Valomaciclovir can be decreased when combined with Moxifloxacin.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Moxifloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Moxifloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Moxifloxacin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Moxifloxacin.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be increased when used in combination with Moxifloxacin.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be increased when used in combination with Moxifloxacin.Approved, Investigational
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Moxifloxacin.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Moxifloxacin.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Moxifloxacin.Approved
XanthineThe metabolism of Xanthine can be decreased when combined with Moxifloxacin.Experimental
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
ZincZinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc acetateZinc acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc ascorbateZinc ascorbate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Zinc carbonateZinc carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc cationZinc cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc chlorideZinc chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc citrateZinc citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc DibutyldithiocarbamateZinc Dibutyldithiocarbamate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc gluconateZinc gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Zinc glycinateZinc glycinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc oxideZinc oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc picolinateZinc picolinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc Substituted Heme CZinc Substituted Heme C can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc sulfateZinc sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc sulfate, unspecified formZinc sulfate, unspecified form can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Zinc TrihydroxideZinc Trihydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Drink liberally. Absorption is not affected by lipid-rich meals or yogourt.

References

Synthesis Reference

Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, "Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof." U.S. Patent US20050137227, issued June 23, 2005.

US20050137227
General References
  1. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. [PubMed:14614666]
External Links
Human Metabolome Database
HMDB0014363
KEGG Drug
D08237
KEGG Compound
C07663
PubChem Compound
152946
PubChem Substance
46508509
ChemSpider
134802
BindingDB
50366824
ChEBI
63611
ChEMBL
CHEMBL32
Therapeutic Targets Database
DAP000158
PharmGKB
PA450555
HET
MFX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Moxifloxacin
ATC Codes
J01MA14 — MoxifloxacinS01AE07 — Moxifloxacin
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.18 — Quinolones
PDB Entries
2xkk / 3fof / 4z2c / 4z3o / 5bs8 / 5bta / 5cdq
FDA label
Download (162 KB)
MSDS
Download (193 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableAlzheimer's Disease (AD)1
1CompletedNot AvailableCardiac Repolarization / Healthy Volunteers1
1CompletedNot AvailableCardiodynamics / Pharmacokinetics / Safety / Tolerability1
1CompletedNot AvailableClinical Pharmacology, Healthy Volunteer Study1
1CompletedNot AvailableContraception1
1CompletedNot AvailableFunctional Dyspepsia1
1CompletedNot AvailableHealthy Volunteers15
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHeart Repolarization1
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedNot AvailableHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
1CompletedNot AvailableLice Infestations1
1CompletedNot AvailableQt Interval, Variation in1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceAmount of NKTR-118 in Blood / Variation in the Heart's Electrical Cycle1
1CompletedBasic ScienceAsthma Bronchial1
1CompletedBasic ScienceBacterial Infections1
1CompletedBasic ScienceC-Peptide Effects on the QT/QTc Interval / Effects of Different Meals on the QT/QTc Interval / Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use / Japanese vs. Caucasian TQT Comparison / Moxifloxacin ECG Profile in Fed and Fasted State1
1CompletedBasic ScienceChronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD)1
1CompletedBasic ScienceDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceEffects of Sativex on ECG1
1CompletedBasic ScienceFibromyalgia1
1CompletedBasic ScienceHealthy Male Volunteers1
1CompletedBasic ScienceHealthy Volunteers16
1CompletedBasic ScienceHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedBasic ScienceInfection NOS1
1CompletedBasic ScienceMalignant Lymphomas / Refractory Solid Tumors1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceRestless Legs Syndrome (RLS)1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedBasic ScienceTTR Cardiomyopathy1
1CompletedBasic ScienceTumors, Solid1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedDiagnosticHealthy Volunteers1
1CompletedDiagnosticHuman Volunteers1
1CompletedDiagnosticTherapeutic Agent Toxicity1
1CompletedDiagnosticThe Effect of Moxifloxacin on QT/QTc Interval1
1CompletedEducational/Counseling/TrainingPatients With Pace Makers But no Evidence of Ischemic Heart Disease1
1CompletedOtherCardiovascular Abnormalities1
1CompletedOtherHealthy Volunteers4
1CompletedOtherMalaria caused by plasmodium vivax1
1CompletedOtherNausea and Vomiting, Postoperative / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedOtherTuberculosis1
1CompletedPreventionHealthy Volunteers3
1CompletedScreeningCataract Extraction1
1CompletedScreeningHealthy Volunteers1
1CompletedTreatmentAcne Vulgaris1
1CompletedTreatmentAcute Coronary Syndromes (ACS)1
1CompletedTreatmentAlzheimer's Disease (AD) / Healthy Volunteers1
1CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1CompletedTreatmentAnemias2
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCardiac Conduction and Repolarization1
1CompletedTreatmentCardiac Effects in Normal Healthy Volunteers1
1CompletedTreatmentCardiac Repolarization in Healthy Subjects1
1CompletedTreatmentCardiac Repolarization / Healthy Volunteers1
1CompletedTreatmentChronic Lung Diseases / Moxifloxacin / Pulmonary Diseases1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
1CompletedTreatmentDyslipidemias2
1CompletedTreatmentECG Effects1
1CompletedTreatmentElectrocardiography / QTc Evaluation1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHealthy Adult Male and Female Volunteers1
1CompletedTreatmentHealthy Volunteers53
1CompletedTreatmentHepatitis C Viral Infection2
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1CompletedTreatmentHuman Experimentation (Human Volunteers)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentNormal Healthy Subjects1
1CompletedTreatmentObstetric Labour, Premature1
1CompletedTreatmentOccasional Constipation1
1CompletedTreatmentParkinson's Disease (PD)2
1CompletedTreatmentPhenylketonuria (PKU)1
1CompletedTreatmentPostoperative pain1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentQT Interval1
1CompletedTreatmentQTc Interval1
1CompletedTreatmentQt Interval, Variation in1
1CompletedTreatmentRenal Cell Adenocarcinoma / Tumors, Solid1
1CompletedTreatmentRespiratory Tract Infections (RTI)1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders1
1CompletedTreatmentTuberculosis1
1CompletedTreatmentTumors, Solid1
1Not Yet RecruitingBasic ScienceDiabetes Mellitus (DM)1
1Not Yet RecruitingBasic ScienceElectrocardiogram Repolarisation Abnormality / Gonorrhoea1
1RecruitingBasic ScienceCoronary Artery Disease1
1RecruitingOtherHealthy Volunteers3
1RecruitingTreatmentCongestive Heart Failure (CHF)1
1RecruitingTreatmentDyslipidemias1
1RecruitingTreatmentHealthy Participants / Systemic Lupus Erythematosus (SLE)1
1RecruitingTreatmentHealthy Volunteers1
1TerminatedBasic ScienceHealthy Males1
1TerminatedOtherHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
1TerminatedTreatmentMycobacterium Tuberculosis1
1Unknown StatusTreatmentCardiac Toxicity1
1WithdrawnTreatmentAlzheimer's Disease (AD)1
1WithdrawnTreatmentAsthma Bronchial1
1WithdrawnTreatmentBacterial Infections2
1WithdrawnTreatmentTuberculosis1
1, 2CompletedPreventionRecurrent Tuberculosis1
1, 2CompletedTreatmentTB Multi-drug Resistant1
2CompletedNot AvailableCancers / Tumors, Solid1
2CompletedBasic ScienceHealthy Volunteers1
2CompletedBasic ScienceTuberculosis1
2CompletedPreventionEndophthalmitis1
2CompletedTreatmentAcute Otitis Media1
2CompletedTreatmentCholangitis1
2CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2CompletedTreatmentConjunctivitis, Bacterial1
2CompletedTreatmentOff Episodes of Parkinson Disease / Parkinson's Disease (PD)1
2CompletedTreatmentPharmacodynamics / Pharmacokinetics / Tolerability / Tuberculous Meningitis1
2CompletedTreatmentPneumonia1
2CompletedTreatmentSpasticity1
2CompletedTreatmentTuberculosis6
2CompletedTreatmentTuberculosis, Pulmonary4
2RecruitingTreatmentDrug-resistant Tuberculosis / Drug-Resistant Tuberculosis, Extremely / Tuberculosis / Tuberculosis, MDR / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2TerminatedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2TerminatedTreatmentCorneal Infiltrates1
2TerminatedTreatmentOsteomyelitis1
2TerminatedTreatmentUlcerative keratitis1
2Unknown StatusTreatmentTuberculosis1
2, 3Not Yet RecruitingPreventionEndophthalmitis1
2, 3RecruitingTreatmentExtensively Drug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2, 3RecruitingTreatmentExtensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
3CompletedPreventionBacteremia / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
3CompletedPreventionChronic Bronchitis / Chronic Lung Diseases1
3CompletedTreatmentAbscesses / Diabetic Foot / Ulcers / Wound Infections1
3CompletedTreatmentAcute Bacterial Conjunctivitis1
3CompletedTreatmentAcute Calculous Cholecystitis1
3CompletedTreatmentAcute Otitis Externa1
3CompletedTreatmentAcute Otitis Media1
3CompletedTreatmentChronic Bronchitis1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)2
3CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)2
3CompletedTreatmentCommunity-Acquired Infections / Pneumonia, Bacterial1
3CompletedTreatmentConjunctivitis, Bacterial2
3CompletedTreatmentBacterial blepharitis / Conjunctivitis / Corneal Inflammation1
3CompletedTreatmentInfection NOS1
3CompletedTreatmentInfectious Diseases1
3CompletedTreatmentIntra-Abdominal Infections1
3CompletedTreatmentIntraabdominal Infections1
3CompletedTreatmentLung Abscess / Pneumonia, Aspiration1
3CompletedTreatmentPelvic Inflammatory Disease (PID)2
3CompletedTreatmentPneumonia2
3CompletedTreatmentSevere Sepsis / Shock, Septic1
3CompletedTreatmentSinusitis1
3CompletedTreatmentTuberculosis, Pulmonary1
3CompletedTreatmentTuberculosis, Pulmonary, Drug Sensitive / Tuberculosis, Pulmonary, Multi Drug-resistant1
3Not Yet RecruitingTreatmentCataract operation / Endophthalmitis / Intracameral Antibiotics / Moxifloxacin / Phacoemulsification / Vancomycin1
3RecruitingTreatmentAtypical; Mycobacterium, Pulmonary, Tuberculous1
3RecruitingTreatmentCommunity Acquired Bacterial Pneumonia / Community Acquired Pneumonia (CAP)1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
3RecruitingTreatmentMDR-TB1
3RecruitingTreatmentTuberculosis2
3RecruitingTreatmentTuberculosis, Multidrug Resistant1
3TerminatedPreventionEndophthalmitis1
3TerminatedSupportive CareCancer of the Ovary / Cancer, Breast / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neuroblastomas / Testicular germ cell tumour1
3TerminatedTreatmentAcute Otitis Media1
3TerminatedTreatmentSkin Diseases, Infectious1
3TerminatedTreatmentTuberculous infections1
3Unknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3Unknown StatusPreventionEye Infections1
3Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Gastritis Chronic1
3Unknown StatusTreatmentCellulitis1
3WithdrawnTreatmentSkin Structures and Soft Tissue Infections1
4CompletedNot AvailableAbscesses / Cysts1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableCataract operation / Corneal Health1
4CompletedNot AvailableConjunctivitis, Bacterial1
4CompletedBasic ScienceAnti-Biotic Resistance1
4CompletedBasic ScienceCataracts1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceSide-effect of Antibiotic1
4CompletedOtherCataract Extraction1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionCataracts1
4CompletedSupportive CareBacterial Infections / Cataract Extraction / Eye Infections1
4CompletedSupportive CareBacterial Infections / Eye Infections2
4CompletedSupportive CareGeneralized Aggressive Periodontitis / Periodontitis, Aggressive1
4CompletedTreatmentBody Weights / Bypass, Gastric1
4CompletedTreatmentCataract Extraction1
4CompletedTreatmentCataracts1
4CompletedTreatmentChronic Bronchitis1
4CompletedTreatmentChronic Generalized Periodontitis1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentConjunctivitis1
4CompletedTreatmentConjunctivitis, Bacterial2
4CompletedTreatmentEye Infections, Bacterial / Ulcerative keratitis1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentIntra-Abdominal Infections1
4CompletedTreatmentMaxillary Sinusitis1
4CompletedTreatmentPelvic Inflammatory Disease (PID)1
4CompletedTreatmentPeriodontitis, Chronic1
4CompletedTreatmentPneumonia1
4CompletedTreatmentProlonged QTc Interval1
4CompletedTreatmentHepatic abscess1
4Enrolling by InvitationPreventionCardiac Dysrhythmia1
4Not Yet RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingPreventionCataracts / Endophthalmitis / Macula Edema1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedBasic ScienceTransplantation, Corneal1
4TerminatedTreatmentBacterial Infections / Sinusitis1
4TerminatedTreatmentCommunity Acquired Pneumonia (CAP)1
4TerminatedTreatmentTuberculosis1
4Unknown StatusPreventionCataracts1
4Unknown StatusPreventionEye Infections / Infection NOS1
4Unknown StatusTreatmentCommunity Acquired Pneumonia (CAP)1
4Unknown StatusTreatmentIntravitreal Injection Patients1
4Unknown StatusTreatmentReinfection Pulmonary Tuberculosis1
Not AvailableActive Not RecruitingDiagnosticLong qt Syndrome1
Not AvailableCompletedNot AvailableAbscess, Intra-Abdominal / Secondary Peritonitis1
Not AvailableCompletedNot AvailableAcute Bacterial Sinusitis (ABS)1
Not AvailableCompletedNot AvailableAnti-Infective Agents1
Not AvailableCompletedNot AvailableBronchial Diseases / Chronic Bronchitis1
Not AvailableCompletedNot AvailableChronic Bronchitis2
Not AvailableCompletedNot AvailableChronic Bronchitis / Disease Exacerbation1
Not AvailableCompletedNot AvailableCorneal Epithelial Wound Healing1
Not AvailableCompletedNot AvailableDrug-Induced Liver Injury1
Not AvailableCompletedNot AvailablePneumonia1
Not AvailableCompletedNot AvailableSkin Diseases, Bacterial1
Not AvailableCompletedHealth Services ResearchHealthy Volunteers1
Not AvailableCompletedPreventionAge-Related Macular Degeneration (ARMD)1
Not AvailableCompletedPreventionInflammation Following Cataract Surgery1
Not AvailableCompletedPreventionPost Lasik Surgery Inflammation1
Not AvailableCompletedTreatmentEpithelium, Corneal1
Not AvailableCompletedTreatmentPeritoneal Dialysis Associated Peritonitis1
Not AvailableCompletedTreatmentPneumonia, Mycoplasma1
Not AvailableEnrolling by InvitationOtherAppendicitis Acute1
Not AvailableNot Yet RecruitingNot AvailableCommunity Acquired Pneumonia (CAP)1
Not AvailableRecruitingNot AvailableTuberculosis1
Not AvailableRecruitingTreatmentAppendicitis Acute1
Not AvailableRecruitingTreatmentBronchiectasis1
Not AvailableRecruitingTreatmentDrug-resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
Not AvailableRecruitingTreatmentHelicobacter Infection2
Not AvailableTerminatedSupportive CareChronic Myeloproliferative Disorders / Fever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neutropenias / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableUnknown StatusTreatmentQT Interval Prolongation1
Not AvailableWithdrawnPreventionConjunctical Flora1

Pharmacoeconomics

Manufacturers
  • Bayer healthcare pharmaceuticals inc
  • Alcon inc
  • Bayer Healthcare Pharmaceuticals
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Alcon Laboratories
  • A-S Medication Solutions LLC
  • Bayer Healthcare
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Fresenius Kabi AB
  • H.J. Harkins Co. Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Redpharm Drug
  • Schering Corp.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
Dosage forms
FormRouteStrength
SolutionOphthalmic0.5 %
Injection, solutionIntravenous400 mg/250mL
TabletOral400 mg
Tablet, film coatedOral400 mg/1
SolutionIntravenous400 mg
Injection, solutionOphthalmic
Injection, solutionIntraocular
TabletOral400 mg/1
Injection, solutionIntraocular5 mg/mL
Injection, solutionOphthalmic5 mg/mL
Injection, suspensionOphthalmic
SuspensionOphthalmic
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Vigamox 0.5% Solution 3ml Bottle90.72USD bottle
Vigamox 0.5% eye drops27.22USD ml
Avelox 400 mg tablet16.68USD tablet
Avelox abc pack 400 mg tablet16.35USD tablet
Avelox iv 400 mg/250 ml0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4990517No1994-12-082011-12-08Us
CA2342211No2009-05-262019-09-29Canada
CA1340114No1998-11-032015-11-03Canada
US5849752No1996-12-052016-12-05Us
US6610327No1999-10-292019-10-29Us
US6548079No2000-07-252020-07-25Us
US7671070Yes2000-03-292020-03-29Us
US6716830Yes2000-03-292020-03-29Us
US8450311No2009-05-292029-05-29Us
US9114168No2009-05-292029-05-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)238-242 °CNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.168 mg/mLALOGPS
logP0.01ALOGPS
logP-0.5ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)5.69ChemAxon
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.22 m3·mol-1ChemAxon
Polarizability41.24 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9794
Blood Brain Barrier-0.9597
Caco-2 permeable-0.6093
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor INon-inhibitor0.7564
P-glycoprotein inhibitor IINon-inhibitor0.7181
Renal organic cation transporterNon-inhibitor0.7318
CYP450 2C9 substrateNon-substrate0.8018
CYP450 2D6 substrateNon-substrate0.8247
CYP450 3A4 substrateNon-substrate0.5756
CYP450 1A2 substrateNon-inhibitor0.7417
CYP450 2C9 inhibitorNon-inhibitor0.7735
CYP450 2D6 inhibitorNon-inhibitor0.8359
CYP450 2C19 inhibitorNon-inhibitor0.7401
CYP450 3A4 inhibitorNon-inhibitor0.8811
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5536
Ames testAMES toxic0.6227
CarcinogenicityNon-carcinogens0.9038
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8092
hERG inhibition (predictor II)Non-inhibitor0.6461
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0176900000-5ca9cd234a2a93f05658
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0391000000-7a74ddcc516a82243c1a

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyrrolopyridines / Pyridinecarboxylic acids / Methoxyanilines / Dialkylarylamines / Anisoles
show 15 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyrrolopyridine / Pyridine carboxylic acid or derivatives / Pyridine carboxylic acid / Methoxyaniline
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, cyclopropanes, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid, pyrrolidinopiperidine (CHEBI:63611)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998]
  4. Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688]
  5. Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J: Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol. 2004 Mar;42(3):1185-91. [PubMed:15004073]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
  4. Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935]
  5. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC: gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. [PubMed:12384345]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I: Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. [PubMed:20596674]
  3. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD: Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29. [PubMed:20802486]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10. [PubMed:19590965]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 13:44